Linsidomine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Linsidomine
DrugBank Accession Number
DB13400
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 170.172
Monoisotopic: 170.080375578
Chemical Formula
C6H10N4O2
Synonyms
  • Linsidomina
  • Linsidomine
  • Linsidominum
External IDs
  • CV 664

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of bleeding can be increased when Linsidomine is combined with Abciximab.
AcebutololAcebutolol may increase the hypotensive activities of Linsidomine.
AceclofenacThe risk or severity of bleeding can be increased when Aceclofenac is combined with Linsidomine.
AcemetacinThe risk or severity of bleeding can be increased when Acemetacin is combined with Linsidomine.
AcenocoumarolThe risk or severity of bleeding can be increased when Linsidomine is combined with Acenocoumarol.
Acetylsalicylic acidAcetylsalicylic acid may increase the antiplatelet activities of Linsidomine.
AlclofenacThe risk or severity of bleeding can be increased when Alclofenac is combined with Linsidomine.
AldesleukinThe risk or severity of bleeding can be increased when Aldesleukin is combined with Linsidomine.
AlemtuzumabThe risk or severity of bleeding can be increased when Linsidomine is combined with Alemtuzumab.
AlfentanilAlfentanil may decrease the antihypertensive activities of Linsidomine.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Linsidomine hydrochlorideY0054U597M16142-27-1ZRFWHHCXSSACAW-UHFFFAOYSA-M

Categories

ATC Codes
C01DX18 — Linsidomine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as morpholines. These are organic compounds containing a morpholine moiety, which consists of a six-member aliphatic saturated ring with the formula C4H9NO, where the oxygen and nitrogen atoms lie at positions 1 and 4, respectively.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Oxazinanes
Sub Class
Morpholines
Direct Parent
Morpholines
Alternative Parents
Heteroaromatic compounds / 1,2,3-oxadiazoles / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
Substituents
1,2,3-oxadiazole / Aromatic heteromonocyclic compound / Azacycle / Azole / Dialkyl ether / Ether / Heteroaromatic compound / Hydrocarbon derivative / Morpholine / Organic nitrogen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
5O5U71P6VQ
CAS number
33876-97-0
InChI Key
FKDHHVKWGRFRTG-UHFFFAOYSA-N
InChI
InChI=1S/C6H10N4O2/c7-6-5-10(8-12-6)9-1-3-11-4-2-9/h5,7H,1-4H2
IUPAC Name
5-azanidyl-3-(morpholin-4-yl)-1,2,3lambda5-oxadiazol-3-ylium
SMILES
[NH-]C1=C[N+](=NO1)N1CCOCC1

References

General References
Not Available
ChemSpider
10561427
BindingDB
83470
ChEBI
136004
ChEMBL
CHEMBL1189150
Wikipedia
Linsidomine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility31.2 mg/mLALOGPS
logP-1.2ALOGPS
logP-2.1ChemAxon
logS-0.86ALOGPS
pKa (Strongest Acidic)10.06ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area62.61 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity60.32 m3·mol-1ChemAxon
Polarizability16.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on June 23, 2017 20:41 / Updated on February 21, 2021 18:54